These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11894021)

  • 1. Determinants of response and resistance to cytotoxics.
    Rosell R; Monzó M; Alberola V; Taron M; Barnadas A; Sánchez JM; Manzano JL; Sanchez JJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):110-8. PubMed ID: 11894021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug resistance in non-small cell lung cancer.
    Monzo M; Rosell R; Taron M
    Lung Cancer; 2001 Dec; 34 Suppl 2():S91-4. PubMed ID: 11720748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic testing for chemotherapy in non-small cell lung cancer.
    Rosell R; Taron M; Alberola V; Massuti B; Felip E
    Lung Cancer; 2003 Aug; 41 Suppl 1():S97-102. PubMed ID: 12867068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group.
    Ramirez JL; Rosell R; Taron M; Sanchez-Ronco M; Alberola V; de Las Peñas R; Sanchez JM; Moran T; Camps C; Massuti B; Sanchez JJ; Salazar F; Catot S;
    J Clin Oncol; 2005 Dec; 23(36):9105-12. PubMed ID: 16361617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
    d'Amato TA; Landreneau RJ; Ricketts W; Huang W; Parker R; Mechetner E; Yu IR; Luketich JD
    J Thorac Cardiovasc Surg; 2007 Feb; 133(2):352-63. PubMed ID: 17258563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of genetic markers on survival in non-small cell lung cancer.
    Rosell R; Taron M; Camps C; López-Vivanco G
    Drugs Today (Barc); 2003 Oct; 39(10):775-86. PubMed ID: 14668933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.
    Rosell R; Scagliotti G; Danenberg KD; Lord RV; Bepler G; Novello S; Cooc J; Crinò L; Sánchez JJ; Taron M; Boni C; De Marinis F; Tonato M; Marangolo M; Gozzelino F; Di Costanzo F; Rinaldi M; Salonga D; Stephens C
    Oncogene; 2003 Jun; 22(23):3548-53. PubMed ID: 12789263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
    Alberola V; Camps C; Provencio M; Isla D; Rosell R; Vadell C; Bover I; Ruiz-Casado A; Azagra P; Jiménez U; González-Larriba JL; Diz P; Cardenal F; Artal A; Carrato A; Morales S; Sanchez JJ; de las Peñas R; Felip E; López-Vivanco G;
    J Clin Oncol; 2003 Sep; 21(17):3207-13. PubMed ID: 12947054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer.
    Stewart DJ; Tomiak E; Shamji FM; Maziak DE; MacLeod P
    Lung Cancer; 2004 May; 44(2):241-9. PubMed ID: 15084389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy in combination with gemcitabine in non-small cell lung cancer.
    Rosell R; Crino L; Danenberg K; Scagliotti G; Bepler G; Taron M; Alberola V; Provencio M; Camps C; De Marinis F; Sanchez JJ; Peñas R
    Semin Oncol; 2003 Aug; 30(4 Suppl 10):19-25. PubMed ID: 12917817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.
    Zinner RG; Glisson BS; Fossella FV; Pisters KM; Kies MS; Lee PM; Massarelli E; Sabloff B; Fritsche HA; Ro JY; Ordonez NG; Tran HT; Yang Y; Smith TL; Mass RD; Herbst RS
    Lung Cancer; 2004 Apr; 44(1):99-110. PubMed ID: 15013588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC.
    Samakoglu S; Deevi DS; Li H; Wang S; Murphy M; Bao C; Bassi R; Prewett M; Tonra JR
    Cancer Genomics Proteomics; 2012; 9(2):77-92. PubMed ID: 22399498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial.
    Sun JM; Ahn JS; Jung SH; Sun J; Ha SY; Han J; Park K; Ahn MJ
    J Clin Oncol; 2015 Aug; 33(22):2450-6. PubMed ID: 26124486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer.
    Alberola V; Sarries C; Rosell R; Taron M; de las Peñas R; Camps C; Massuti B; Insa A; Garcia-Gomez R; Isla D; Artal A; Muñoz MA; Cobo M; Bover I; Gonzalez-Larria JL; Terrasa J; Almenar D; Barcelo R; Diz P; Sanchez-Ronco M; Sanchez JJ
    Clin Lung Cancer; 2004 May; 5(6):360-5. PubMed ID: 15217535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
    Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G;
    Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
    Mlak R; Krawczyk P; Homa-Mlak I; Powrózek T; Ciesielka M; Kozioł P; Milanowski J; Małecka-Massalska T
    Pathol Oncol Res; 2019 Jul; 25(3):1035-1045. PubMed ID: 30066234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer.
    Yuan ZJ; Zhou WW; Liu W; Wu BP; Zhao J; Wu W; He Y; Yang S; Su J; Luo Y
    Asian Pac J Cancer Prev; 2015; 16(10):4347-51. PubMed ID: 26028097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect evaluation of cisplatin-gemcitabine combination chemotherapy for advanced non-small cell lung cancer patients using microarray data.
    Ma GF; Zhang RF; Ying KJ; Wang D
    Eur Rev Med Pharmacol Sci; 2015 Feb; 19(4):578-85. PubMed ID: 25753874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer.
    Han JY; Lee GK; Lim KY; Lee YJ; Nam BH; Lee JS
    Cancer Res Treat; 2017 Jul; 49(3):678-687. PubMed ID: 27737534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
    de Fraipont F; Levallet G; Creveuil C; Bergot E; Beau-Faller M; Mounawar M; Richard N; Antoine M; Rouquette I; Favrot MC; Debieuvre D; Braun D; Westeel V; Quoix E; Brambilla E; Hainaut P; Moro-Sibilot D; Morin F; Milleron B; Zalcman G;
    Clin Cancer Res; 2012 May; 18(10):2976-86. PubMed ID: 22434665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.